U.S. Life Sciences Stock News

In early March 2026, PACS Group, Inc. appointed Patrick H. Conway, MD, MSc, the CEO of Optum and former senior CMS leader, to its Board of Directors, adding a rare mix of clinical, regulatory, and large-scale health system leadership to its governance. This move brings to PACS Group a director who helped design major U.S. value-based payment models and still practices medicine, potentially sharpening the company’s focus on quality and reimbursement innovation in post-acute and skilled...

If you are wondering whether Vertex Pharmaceuticals at around US$492 per share is still a good deal or already pricing in a lot of optimism, you are asking the right question for any valuation focused investor. The stock has returned 3.0% over the last week, 4.6% over the last month, 8.9% year to date, while the 1 year return sits at a slight 0.6% decline and the 3 and 5 year returns are 67.3% and 126.8% respectively. This naturally raises questions about how much of the story is already in...

UL Solutions recently granted its first UL 3300 safety certification for a publicly operating autonomous robot, approving Simbe’s Tally shelf‑scanning robot for use in dynamic environments such as grocery stores. This milestone highlights UL Solutions’ growing role in setting safety benchmarks for autonomous robots in high‑traffic public spaces, a segment gaining increasing attention from technology providers and their customers. We’ll now examine how this first UL 3300 certification for...

If you are looking at Advanced Energy Industries and wondering whether the current share price really stacks up, you are not alone. This article will walk through what that price might imply about value. The stock recently closed at US$314.84, with returns of 12.8% over 30 days, 41.8% year to date and 198.4% over the past year, which can change how investors think about both upside and risk. These moves sit against a backdrop of ongoing interest in power conversion and control solutions, as...

Recent rating upgrades for Dow (DOW) by firms including RBC Capital Markets and Fermium Research have drawn attention to the stock, as analysts highlight polyethylene margin potential and ongoing cost reduction efforts. See our latest analysis for Dow. Those upgrades arrive after a strong run in the shares, with a 7-day share price return of 6.28% and a 90-day share price return of 39.83%, while the 3-year total shareholder return of an 18.65% decline shows a more mixed longer term...

In early March 2026, Ouster, Inc. reported its fourth-quarter and full-year 2025 results, delivering US$62.18 million in quarterly revenue and US$3.99 million in net income, and issued first-quarter 2026 revenue guidance of US$45 million to US$48 million while filing an US$84.43 million shelf registration for common stock tied to an ESOP offering. Alongside its first profitable quarter and the acquisition of Stereolabs to broaden its sensor technology beyond lidar, Ouster also saw insider...

If you are wondering whether Magnite's current share price lines up with its underlying value, you are not alone. This article focuses on what the numbers actually say about the stock. The share price closed at US$13.03, with returns of 11.7% over 30 days, a 5.8% decline over 7 days, a nearly flat 0.1% decline over 1 year, a 55.1% gain over 3 years, and a 73.4% decline over 5 years. Recent coverage around Magnite has centered on its role in the ad tech space and how investors are thinking...

Vanda Pharmaceuticals recently received a decision from the U.S. FDA granting a rare formal evidentiary public hearing to review the agency’s proposed refusal to approve a supplemental new drug application for HETLIOZ (tasimelteon) as a treatment for jet lag disorder. This hearing, which follows Vanda’s earlier legal win requiring the FDA to more fully address its clinical evidence, highlights unusually high regulatory and scientific scrutiny around expanding HETLIOZ into a large, currently...

If you are wondering whether Papa John's International is priced attractively right now, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock closed at US$38.86 recently, with a sharp 26.1% return over the last 7 days and 11.5% over the last 30 days, while year to date the return sits at a 3.6% decline and the 1 year return is a 7.5% decline, compared to a 46.0% decline over 3 years and a 49.9% decline over 5 years. Recent...

If you are wondering whether Corning's current share price still reflects good value after a strong run, you are not alone. This article is built to help you frame that question clearly. Corning's stock closed at US$131.76, with a 7 day return of a 9% decline, a 30 day return of 0.3%, a year to date return of 45.3% and a 1 year return of 194.6%, while the 3 year and 5 year returns sit at 333.7% and 264.4% respectively. Recent price moves are happening alongside ongoing investor interest in...

Universal Display (NasdaqGS:OLED) recently presented a white phosphorescent OLED lighting panel at the SPIE Optics + Photonics Conference. The white PHOLED panel exceeded U.S. Department of Energy targets for commercial panel lifetime. This technical achievement highlights potential commercial use cases for white OLED lighting beyond current display products. Universal Display is best known for its OLED materials and technologies used in smartphone, TV, and other display applications. This...

Ocugen (OCGN) has completed enrollment in its Phase 3 liMeliGhT trial for OCU400 in retinitis pigmentosa, a key clinical milestone that sits alongside fresh financial results and an auditor flagged going concern risk. See our latest analysis for Ocugen. The completion of Phase 3 enrollment and the fresh financial disclosures arrive after a sharp move in Ocugen’s shares, with a 1 day share price return of 29.94% and a 30 day share price return of 66.67%. This has contributed to a 1 year total...

If you are wondering whether Wingstop’s current share price is giving you a fair deal or not, this article will walk through what the numbers are saying about its valuation. After reaching a last close of US$208.66, the stock has seen a 12.8% decline over 7 days and a 25.9% decline over 30 days, even though the 3 year and 5 year returns sit at 20.8% and 67.3% respectively. Recent coverage has focused on Wingstop as a well known US consumer services stock listed on the Nasdaq, which keeps it...

In early March 2026, Planet Labs PBC announced it had been selected as a prime contractor under the Missile Defense Agency’s SHIELD IDIQ contract vehicle, which has a ceiling of US$151.00 billion, while also tightening access to its Middle East imagery with delays of up to 14 days to limit adversarial use. This combination of prime contractor status and stricter imagery controls highlights Planet Labs’ growing role as a provider of sensitive, defense-oriented monitoring services and...

In recent weeks, Quanta Services reported Q4 2025 earnings and revenue above expectations, issued 2026 guidance ahead of analyst estimates, and highlighted a record backlog of about US$44.00 billion driven by grid modernization and large-load infrastructure demand. The company also scheduled a March 31, 2026 Investor Day in New York City to outline new long-term financial targets, signaling management’s focus on turning its growing backlog and recent acquisitions into clearer multi-year...

Markel Group (NYSE:MKL) has appointed Phil Jones as Chief Information Officer, International. The company has also named Kristen Dardia as Head of Portfolio Analytics, US & Bermuda. These appointments expand leadership in technology and analytics across international and specialty insurance markets. Markel Group, a specialty insurance and investment company, is placing additional leadership emphasis on technology and data across its international operations and US & Bermuda books. For you...

VNET Group recently completed a US$138 million private placement of 81 million new Class A shares to support working capital, capital expenditures, and potential corporate transactions, and it has scheduled the release of its fourth-quarter and full-year 2025 results for March 16, 2026. Beyond near-term funding needs, the deal underscores management’s preference for equity financing to strengthen liquidity even as it accepts some shareholder dilution and a concurrent board...

If you are wondering whether Fastly at US$24.05 still offers value after a strong run, you are not alone. This article is set up to unpack what the current price might be implying. The stock shows returns of 20.0% over 7 days, 175.8% over 30 days, 136.0% year to date, 255.8% over 1 year and negative 68.1% over 5 years, which points to a very different picture depending on the timeframe you focus on. These sharp short term moves have come alongside ongoing attention on Fastly's role in edge...

If you are wondering whether Amgen's current share price lines up with its underlying worth, this article walks through the key numbers that matter for value focused investors. Amgen's stock last closed at US$377.64, with returns of 15.3% year to date and 24.6% over the past year, while the 7 day and 30 day moves of a 0.4% decline and 0.5% gain suggest recent trading has been relatively steady. Recent headlines around Amgen have focused on its position within large cap pharmaceuticals and...

If you are wondering whether Lumentum Holdings is still reasonably priced after a strong run, this article will walk through what the current share price might be implying about its value. The stock last closed at US$672.00, with returns of 3.3% over 7 days, 19.8% over 30 days and 74.0% year to date. The 1 year and multi year returns are very large compared to the starting point for those periods. Recent coverage around Lumentum has focused on its position in optical and photonics...

What BridgeBio Pharma’s recent performance tells you right now BridgeBio Pharma (BBIO) has drawn fresh attention after recent share price moves, including a 3.9% decline over the past day and mixed returns over the past week, month, and past 3 months. This has prompted investors to reassess the story. See our latest analysis for BridgeBio Pharma. Zooming out, BridgeBio Pharma’s recent pullback sits alongside a mixed stretch of share price returns over the past quarter and year to date, while...

Alcoa (NYSE:AA) has agreed to sell ten closed industrial sites to buyers in the data center industry. The assets involved are non operational facilities that are being repurposed for technology infrastructure use. The transaction highlights a shift in how Alcoa is using legacy sites that are no longer part of its core production footprint. For investors watching NYSE:AA, this move comes alongside a share price of $66.36 and multi period gains, including 7.8% over the past week and 17.4%...

Oracle (ORCL) just delivered a stronger than expected fiscal third quarter, with cloud and AI infrastructure revenues helping lift results and push its contracted backlog higher, easing earlier worries about heavy data center spending. See our latest analysis for Oracle. The earnings beat and higher AI driven backlog arrived alongside a sharp 1 day share price return of 9.18%, even though the 90 day share price return of a 17.97% decline and year to date share price return of a 16.65% decline...

W. R. Berkley (NYSE:WRB) has appointed Ryan Miller as president of its Berkley Southeast Insurance Group unit. Miller brings over 25 years of commercial insurance operations experience to the regional business. The leadership change is expected to influence management priorities and growth plans in the southeastern U.S. market. For investors tracking W. R. Berkley, the appointment comes at a time when the stock trades at $67.86, with a 1 year return of 13.2% and a 3 year return of 81.4%...